Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-11-30
2010-06-15
Allen, Marianne P (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
Reexamination Certificate
active
07737259
ABSTRACT:
Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided.
REFERENCES:
patent: 5965704 (1999-10-01), Lok et al.
patent: 6274710 (2001-08-01), Dumoutier et al.
patent: 6331613 (2001-12-01), Dumoutier et al.
patent: 6359117 (2002-03-01), Dumoutier et al.
patent: 6551799 (2003-04-01), Gurney et al.
patent: 6740520 (2004-05-01), Goddard et al.
patent: 6875845 (2005-04-01), Presnell et al.
patent: 6897292 (2005-05-01), Presnell et al.
patent: 6939545 (2005-09-01), Jacobs et al.
patent: 7279559 (2007-10-01), Jacobs et al.
patent: 2001/0024652 (2001-09-01), Dumoutier et al.
patent: 2001/0027099 (2001-10-01), Zondag et al.
patent: 2003/0012788 (2003-01-01), Renauld et al.
patent: 2003/0022827 (2003-01-01), Weiss et al.
patent: 2003/0023033 (2003-01-01), Dumoutier et al.
patent: 2003/0157106 (2003-08-01), Jacobs et al.
patent: 2003/0170823 (2003-09-01), Presnell et al.
patent: 2003/0170839 (2003-09-01), Fouser et al.
patent: 2003/0219862 (2003-11-01), Agarwal et al.
patent: 2004/0023341 (2004-02-01), Xu et al.
patent: 2004/0071699 (2004-04-01), Renauld et al.
patent: 2004/0110189 (2004-06-01), Dumoutier et al.
patent: 2004/0152125 (2004-08-01), Presnell et al.
patent: 2004/0156849 (2004-08-01), Gurney
patent: 2004/0180399 (2004-09-01), Renauld et al.
patent: 2004/0209330 (2004-10-01), Xu et al.
patent: 2004/0236075 (2004-11-01), Dumoutier et al.
patent: 2005/0042220 (2005-02-01), Li et al.
patent: 2005/0065321 (2005-03-01), Presnell et al.
patent: 2005/0137129 (2005-06-01), Agarwal et al.
patent: 2005/0153400 (2005-07-01), Jacobs et al.
patent: 2005/0158760 (2005-07-01), Jacobs et al.
patent: 2005/0214314 (2005-09-01), Presnell et al.
patent: 2005/0238648 (2005-10-01), Jacobs et al.
patent: 2005/0271619 (2005-12-01), Dumoutier et al.
patent: 1191035 (2002-03-01), None
patent: 00/24758 (2000-05-01), None
patent: 01/16318 (2001-03-01), None
patent: 01/36467 (2001-05-01), None
patent: 01/98342 (2001-12-01), None
patent: 02/10393 (2002-02-01), None
patent: WO 02/068476 (2002-09-01), None
patent: 03/010290 (2003-02-01), None
patent: WO 03/029262 (2003-04-01), None
patent: WO 2004/085476 (2004-10-01), None
patent: WO 2005/000897 (2005-01-01), None
patent: WO 2007/027714 (2007-03-01), None
patent: WO 2007/027761 (2007-03-01), None
patent: WO 2007/098170 (2007-08-01), None
patent: WO 2007/100643 (2007-09-01), None
patent: WO 2007/149814 (2007-12-01), None
Donnelly, et al., “The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain”, Journal of Leukocyte Biology, vol. 76, pp. 314-321, (2004).
Dumoutier, et al., “Cloning and Characterization of II-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor /IL-22”, Journal of Immunology, vol. 166, No. 12, pp. 7090-7095, (2001).
Dumoutier, et al., “IL-TIF/IL-22: Genomic Organization and Mapping of the Human and Mouse Genes”, Genes and Immunity, vol. 1, pp. 488-494, (2000).
Happel, et al., “Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection”, Journal of Immunology, vol. 170, No. 9, pp. 4432-4436, (2003).
Harrington, et al., “Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages”, Nature Immunology, vol. 6, No. 11, pp. 1123-1132, (2005).
Holscher, et al., “Targeting IL-23 in autoimmunity”, Current Opinion in Investigational Drugs, vol. 6, No. 5, pp. 489-495, (2005).
Kotenko, et al., “Identification, cloning and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity”, Journal of Immunology, vol. 166, No. 12, pp. 7096-7103, (2001).
Langrish, et al., “IL-23 Drives a pathogenic T cell population that induces autoimmune Inflammation”, Journal of Experimental Medicine, vol. 201, No. 2, pp. 233-240, (2005).
Lankford, et al., “A unique role for IL-23 in promoting cellular immunity”, Journal of Leukocyte Biology, vol. 73, No. 1, pp. 49-56, (2003).
Lejeune, et al., “Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10”, The Journal of Biological Chemistry, vol. 277, No. 37, pp. 33676-33682, (2002).
Li, et al., “Temporal associations between interleukin 22 and the extracellular domains of IL-22R and IL-10R2”, International Immunopharmacology, vol. 4, No. 5, pp. 693-708, (2004).
Liang, et al., “Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides”, vol. 203, No. 10, pp. 2271-2279, (2006).
Liu, et al., “Signaling through the murine T cell receptor induces IL-17 production in the absence of costimulation, IL-23 or dendritic cells”, Molecules and Cells, vol. 20, No. 3, pp. 339-347, (2005).
Mangan, et al., “Transforming growth factor-beta induces development of the T(H)17 lineage”, Nature, vol. 441, No. 7090, pp. 231-234, (2006).
Nagakawa, et al., “Expression of interleukin-22 in murine carcinoma cells did not influence tumor growth in vivo but did improve survival of the inoculated hosts”, Scandinavian Journal of Immunology, vol. 60, No. 5, pp. 449-454, (2004).
Pan, et al., “Hydrodynamic gene delivery of interleukin-22 protects the mouse liver from concanavalin A-, carbon tetrachloride-, and Fas ligand-induced injury via activation of STAT3”, Cellular & Molecular. Immunology, vol. 1, No. 1, pp. 43-49, (2004).
Park, et al., A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17, Nature Immunology, vol. 6, No. 11, pp. 1133-1141, (2005).
Radaeva, et al., “Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via stat3 activation”, Hepatology, vol. 39, No. 5, pp. 1332-1342, (2004).
Rutitzky, et al., “CD4 T cells producing pro-inflammatory interleukin-17 mediate high pathology in schistosomiasis”, Mem'orias do instituto oswaldo cruz, vol. 101, Suppl. 1, pp. 327-330, (2006).
Sala, et al., “G(i)-protein-dependent inhibition of IL-12 production is mediated by activation of the phosphatidylinositol 3-kinase-protein 3 kinase B/Akt pathway and JNK”, Journal of Immunology, vol. 175, No. 5, pp. 2994-2999, (2005).
Sutton, et al., “A crucial role for leukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis”, The Journal of Experimental Medicine, vol. 203, No. 7, pp. 1685-1691, (2006).
Trinchieri, et al., “The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses”, Immunity, vol. 19, No. 5, pp. 641-644, (2003).
Vandenbroeck, et al., “Inhibiting Cytokines of the Interleukin-12 Family: Recent Advances and Novel Challenges”, Journal of Pharmacy and Pharmacology, vol. 56, pp. 145-160, (2004).
Weber, et al., “IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase”, Journal of Immunology, vol. 177, No. 11, pp. 8266-8272, (2006).
Weighardt, et al., Identification of a TLR4- and TRIF-dependent activation program of dendritic cells, European Journal of Immunology, vol, 34, No. 2, pp. 558-564, (2004).
Weiss, et al., “Cloning and murine IL-22 receptor alpha 2 and comparison with its human counterpart”, Genes and Immunity, vol. 5, No. 5, pp. 330-336, (2004).
Whittington, et al., ““Interleukin-22: a potential immunomodulatory molecule in the lung”, American Journal of Respiratory Cell and Molecular Biology”, vol. 31, No. 2, pp. 220-226, (2004).
Wilson, et al., “Development, cytokine p
Chen Yvonne M.
Chuntharapai Anan
Danilenko Dimitry
Ouyang Wenjun
Sa Susan
Allen Marianne P
Arnold & Porter LLP
Bernhardt Jeffery P.
Brewster Vicki
Genentech Inc.
LandOfFree
Compositions and methods for the treatment of diseases and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the treatment of diseases and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the treatment of diseases and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4247592